Recursion Pharmaceuticals disclosed a 20% reduction in workforce following a recent decision to narrow its research focus and deprioritize multiple clinical-stage programs. This downsizing reflects challenges in AI-driven drug development amid market pressures and restructuring post-Exscientia merger, signaling cautious investor sentiment and operational reset within the AI biotech sector.